The results indicated that GHET1 was up-regulated in most cancers, including lung squamous cell carcinoma (LUSC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA), and esophageal carcinoma (ESCA) (|Log2FC| Cutoff > 1, q-value < 0.01, Fig. 6). Here, GHET1 is linked to bladder transitional cell carcinoma.